Chidamid, an oral HDAC inhibitor of the benzamide class with specificity for HDAC1, HDAC2, HDAC3, and HDAC10 subtypes, has been approved for the treatment of relapsed or refractory peripheral T cell lymphoma. Here, HDAC3 is linked to peripheral T-cell lymphoma, not otherwise specified.